MD ANDERSON CANCER CENTER and Pfizer will collaborate in the development of immune-based approaches to cancer treatment, the first such agreement made through MD Anderson’s Moon Shots Program immunotherapy platform.
As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing.
